Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Captivate: Ibrutinib + Venetoclax in Treatment-naïve CLL/SLL
NCT02910583Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Sep 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of ibrutinib and venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (5 cohorts), sponsored by Pharmacyclics. Primary endpoints: Disease-Free Survival at 1 year and Complete Response Rate. Started Sep 2016; status: completed.
02
Drugs
ibrutinibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02910583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910583.